Trial intelligence / Profile preview

Dosimetry-based vs standard-dose Lu-177-DOTATOC PRRT in neuroendocrine neoplasms

2024-517240-62-00Phase 2Authorised

Sponsor: Central Denmark Region
Start: Nov 2024
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
Countries: 1

Overview

Phase 2, randomised trial of lutetium Lu 177-edotreotide in apudoma (NET) (2 arms), sponsored by Central Denmark Region. Primary endpoint: Progression-free survival. Planned start Nov 2024; status: authorised.

Drugs

lutetium Lu 177-edotreotide

Conditions

apudoma (NET)

Beyond the preview

Go deeper on 2024-517240-62-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-517240-62-00.